glp-1 agonist drugs oral GLP-1: A Needle-Free Solution for Weight Loss Oral GLP-1-Based Therapeutics in the
Description
PMID 19403868
doi: 10.1172/JCI119060 61 TsengC-CZhangX-YWolfeMM
Over the following decade, rapid advances in molecular biology expanded this framework
After the 56-week treatment period, BMI standard deviation scores (BMI SDS) decreased by a mean of 0.23 in the liraglutide group, with no change in the placebo group
While these medications typically reduce blood pressure modestlya benefit for many patientssome individuals may experience low blood pressure (hypotension) or related symptoms like dizziness and lightheadedness
